Vanguard Global Advisers
IMDX

Vanguard Global Advisers’s Insight Molecular Diagnostics IMDX Stock Holding History

Vanguard Global Advisers’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1K Hold
5,775
– – ﹤0.01% 3192
2026
Q1 		$18.9K Buy
+5,775
New +$33.5K ﹤0.01% 3327

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's IMDX Position: Q2 2026 in Review

Vanguard Global Advisers held its Insight Molecular Diagnostics (IMDX) position steady in Q2 2026 at 5,775 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3192.

Vanguard Global Advisers first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Vanguard Global Advisers held 5,775 shares of Insight Molecular Diagnostics worth $34.1K as of Q2 2026.
  • Vanguard Global Advisers left its Insight Molecular Diagnostics share count unchanged in Q2 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3192 holding.
  • Vanguard Global Advisers first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.